The order nobody places

A Stanford professor. A non-smoker. Stage IV lung cancer, diagnosed in May 2024, the same disease he had spent years pushing to catch earlier. On Sunday NPR profiled Bryant Lin as a patient riding the new wave of treatment. First came a daily pill aimed at his tumor's specific EGFR mutation. When that stopped working a year in, he moved to a newly approved antibody-and-pill combination aimed at the same mutation.

The progress is real. UCLA oncologist Jonathan Goldman told NPR that for these patients, survival "used to be under a year, and now it's often several years and sometimes many years." Then the piece reports, almost in passing, a number that matters more: fewer than half of US lung cancer patients have their tumor genetically tested before treatment starts.

That number is the real story. The bottleneck in lung cancer is no longer the molecule. It's the order. A targeted drug only works on the tumors it targets, and nobody knows which tumor a patient has until someone sends the sample out for comprehensive genomic testing. Without that test, the best drug for a patient's cancer can sit on a pharmacy shelf while they get the treatment designed for the average case. Anyone who has shipped software knows this shape: the feature works, and the rollout is the project.

Goldman ran a New England Journal of Medicine study that found dramatic reductions in recurrence when patients with rare subtypes got targeted drugs as their first treatment. His explanation for why most patients still aren't tested is mundane. Testing isn't yet considered standard of care, and general oncologists aren't always current on a field moving this fast. Nobody is refusing the test. It just isn't the default.

Making it the default is only the start, and screening shows why, one step earlier in the disease. For high-risk patients, an annual low-dose CT scan already is the standard recommendation. According to NPR, 18% of them get one.

A guideline tells a doctor what to order. It doesn't place the order.

Even when the order does go in, the system can still say no. Insurers almost always require prior authorization for the new drugs. Lin is a nationally known expert at an elite medical center, and he still had one $16,000 drug delayed at a critical point in his treatment. The order has to clear twice: once past the doctor, once past the payer.

The case for caution is serious. Standard of care moves slowly on purpose. In the 1990s, tens of thousands of women with breast cancer got high-dose chemotherapy with bone-marrow transplants before randomized trials showed it did no better than conventional treatment. Medicine learned, at great cost, not to chase the newest result.

But that lesson is about treatments, and a test is information. Ordering genomic testing up front commits a patient to nothing. It changes which drug the oncologist picks first, and Goldman's trial shows that getting the first pick right matters. Caution that protects patients from an unproven therapy is no argument for leaving them uninformed about a proven one.

Lin calls himself "a beneficiary of years – of decades – of research." A fellow patient gave him the rule he lives by: survive long enough for the next treatment to come out. Days after NPR spoke to him, his scans showed the cancer progressing again, and his next option is a drug approved last year. So far, the next treatment has kept arriving for him. For some of the patients who are never tested, it arrived years ago. What they're waiting on is the order.